Valneva SE

VLA

Equity

ISIN FR0004056851 / Valor 1184169

Euronext - Euronext Paris (2025-11-18)

EUR 3.78-1.25%

Valneva SE
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Valneva SE is a biotechnology firm dedicated to the development, manufacturing, and commercialization of preventive vaccines for infectious diseases that lack adequate medical solutions. The company has successfully launched three vaccines, including a single-dose chikungunya vaccine, and is actively progressing a diverse pipeline of candidates aimed at diseases such as Lyme disease, Shigella, and Zika virus. By leveraging its specialized expertise in vaccine technology, Valneva focuses on addressing significant public health needs through innovative vaccine development, positioning itself as a key player in the global efforts to prevent and control infectious diseases.

Summarized from source with an LLMView SourceSector: Technology

Total Revenues and Product Sales Growth

For the first half of 2025, Valneva SE achieved total revenues of €97.6 million, marking a 37.8% increase from €70.8 million in the first half of 2024. Product sales surged by 33.3%, reaching €91.0 million compared to €68.3 million in the previous year.

Net Loss and Cash Management

The company reported a net loss of €20.8 million for the first half of 2025, a shift from a net profit of €34.0 million in the same period last year. This change was influenced by the absence of one-time net proceeds from a Priority Review Voucher (PRV) sale. Valneva has significantly reduced its operating cash burn to €10.9 million, down from €66.3 million in the first half of 2024.

Cash Position

As of June 30, 2025, Valneva SE held €161.3 million in cash and cash equivalents, including €20.1 million from two At The Market (ATM) transactions with Novo Holdings A/S and Frazier Life Sciences during Q2 2025. This reflects a stable cash position compared to €168.3 million at the end of December 2024.

Financial Outlook for 2025

Valneva confirmed its 2025 financial guidance, expecting product sales to grow to €170-180 million and total revenues to reach €180-190 million. The company anticipates total R&D investments between €90-100 million, supported by grant funding and R&D tax credits. Valneva emphasizes a continued focus on cash management to achieve over 50% reduction in operating cash burn compared to the prior year.

Summarized from source with an LLMView Source

Key figures

78.9%1Y

-46.1%3Y

-31.6%5Y

Performance

73.3%1Y

58.8%3Y

75.6%5Y

Volatility